1. HBW Insight
  2. >>Health
  4. >>Regulation

US FDA Finds Phenylephrine Ineffective As Nasal Decongestant, Looks At Removing From Monograph

Agency Asks For NDAC Input On 'Unintended Consequences' On Consumers, Industry

 
• By Malcolm Spicer

Phenylephrine doesn’t meet efficacy bar within “generally regarded as safe and effective” standard for OTC monograph drugs, agency says in briefing prepared for NDAC meeting on 11-12 September. FDA say it is “concerned about avoiding potential unintended consequences with regard to changing the GRASE status of oral PE.”

FDA asks for more input whether NDAC members say yes or no on oral phenylephrine's efficacy as a nasal decongestant. • Source: Shutterstock

The US Food and Drug Administration says potential impact on consumers and the drug industry will influence whether it decides to remove oral phenylephrine from its OTC nasal decongestant monograph after concluding that it isn’t effective in doses up to the highest studied level.

The Office of Nonprescription Drugs and other offices and divisions in the agency’s Center for Drug Evaluation and Research explain...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

Senate HELP Committee Adds Sunscreen Regulation Overhaul To OMUFA Reauthorization

 
• By Lauren Nardella

OMUFA reauthorization bill including amendment with sunscreen regulation provisions passed by Senate committee, which also approved other provisions not included in House OMUFA bill.

Urban Wastewater Directive: AESGP Requests Intervention In EFPIA’s Legal Action

 
• By David Ridley

AESGP has formally submitted a request to the General Court of the European Union to intervene in the European Federation of Pharmaceutical Industries and Association’s legal action against the revised EU Urban Wastewater Directive.

Sunscreen Regulation Reforms Still Could Hitch Ride On Senate OMUFA Reauthorization Bill

As stakeholders and lawmakers pin their hopes on OMUFA reauthorization as a vehicle for enacting sunscreen regulatory changes, Senate version of the bill could be the ticket after a sunscreen-specific amendment withdrawn in the House.